Micro-X Ltd (ASX: MX1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Micro-X Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Micro-X Ltd (ASX: MX1)
Latest News
Small Cap Shares
Morgans names 2 small cap ASX shares to buy
Small Cap Shares
Morgans says these small cap ASX shares can rocket 50% to 100%+
Healthcare Shares
Guess which ASX medical tech share soared 37% at one point today
Broker Notes
Top brokers name 3 ASX small cap shares to buy
Broker Notes
Morgans picks small cap ASX shares with near-term share price catalysts
MX1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Micro-X Ltd
Micro-X Ltd operates in the medical industry. The company is engaged in the design, development, manufacturing, and commercialisation of imaging products for the healthcare and security markets utilising Micro-X's proprietary cold cathode X-ray technology. Its products include Head CT, Rover, Argus, Checkpoints, and Baggage CT Scanner imaging devices. In addition, the group also offers custom imaging solutions based on the specific requirements of its customers. Its geographical operating segments are the United States, which generates maximum revenue, and Australia.
MX1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.09 | $0.00 | 0.00% | 252,184 | $0.09 | $0.09 | $0.09 |
| 05 Feb 2026 | $0.09 | $0.00 | 0.00% | 21,091 | $0.09 | $0.09 | $0.09 |
| 04 Feb 2026 | $0.09 | $0.00 | 0.00% | 115,642 | $0.09 | $0.09 | $0.09 |
| 03 Feb 2026 | $0.09 | $0.00 | 0.00% | 167,900 | $0.09 | $0.09 | $0.09 |
| 02 Feb 2026 | $0.09 | $0.00 | 0.00% | 685,935 | $0.09 | $0.09 | $0.09 |
| 30 Jan 2026 | $0.09 | $0.00 | 0.00% | 388,456 | $0.09 | $0.09 | $0.09 |
| 29 Jan 2026 | $0.09 | $0.00 | 0.00% | 64,518 | $0.09 | $0.09 | $0.09 |
| 28 Jan 2026 | $0.09 | $0.00 | 0.00% | 455,171 | $0.09 | $0.09 | $0.09 |
| 27 Jan 2026 | $0.09 | $0.00 | 0.00% | 77,062 | $0.09 | $0.09 | $0.09 |
| 23 Jan 2026 | $0.09 | $0.00 | 0.00% | 80,276 | $0.09 | $0.09 | $0.09 |
| 22 Jan 2026 | $0.09 | $0.00 | 0.00% | 184,071 | $0.09 | $0.09 | $0.09 |
| 21 Jan 2026 | $0.09 | $0.00 | 0.00% | 74,277 | $0.09 | $0.09 | $0.09 |
| 20 Jan 2026 | $0.09 | $0.00 | 0.00% | 136,850 | $0.09 | $0.09 | $0.09 |
| 19 Jan 2026 | $0.09 | $0.00 | 0.00% | 75,420 | $0.09 | $0.09 | $0.09 |
| 16 Jan 2026 | $0.09 | $0.00 | 0.00% | 132,106 | $0.09 | $0.09 | $0.09 |
| 15 Jan 2026 | $0.09 | $0.01 | 11.49% | 347,058 | $0.09 | $0.09 | $0.09 |
| 14 Jan 2026 | $0.09 | $0.00 | 0.00% | 94,806 | $0.09 | $0.09 | $0.09 |
| 13 Jan 2026 | $0.09 | $0.00 | 0.00% | 169,684 | $0.08 | $0.09 | $0.08 |
| 12 Jan 2026 | $0.08 | $0.00 | 0.00% | 313,047 | $0.09 | $0.09 | $0.08 |
| 09 Jan 2026 | $0.09 | $0.00 | 0.00% | 75,729 | $0.09 | $0.09 | $0.09 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Jan 2026 | Ilona Meyer | Expiry | 127,877 | $10,997 |
As advised by the company. Expiry of Performance Rights
|
| 08 May 2025 | Andrew Hartmann | Issued | 357,143 | $25,000 |
Placement.
|
| 08 May 2025 | Patrick O'Brien | Issued | 1,428,571 | $100,000 |
Placement.
|
| 08 May 2025 | James (Jim) McDowell | Issued | 714,286 | $50,000 |
Placement.
|
| 08 May 2025 | Ilona Meyer | Issued | 357,143 | $25,000 |
Placement.
|
| 20 Mar 2025 | Ilona Meyer | Issued | 21,082 | $1,475 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Patrick Gerard O'Brien | Non-Executive Director | Aug 2015 |
Mr O'Brien is Managing Director of Patrick O'Brien & Associates, Chairman of GCQ Funds Management and CE Bartlett, and a Director of The Water & Carbon Group Holdings. He was previously a non-executive director of Red Rock Leisure (1999-2020) and Chairman of the Paywise Group (2019-2023) having led a management buyout through a divestment. He has also chaired or been a board member of several early-stage ventures, not-for-profit organizations and philanthropic foundations. Patrick has over 35 years of business experience in Australia, the UK, Europe, Asia and the US, including as a Senior Managing Director with Macquarie Group where he led teams in corporate finance (Melbourne 1996-2005) and private equity (London 2005-2009). Prior to Macquarie, Patrick was a strategy consultant with McKinsey & Company and a lawyer with Minter Ellison. He is the member of Risk Committee and People Committee.
|
| Mr James (Jim) White McDowell | Non-Executive Director | Jan 2021 |
Mr McDowell is Former Deputy Secretary, Naval Shipbuilding and Sustainment - Australian Department of Defence and prior to this role was Chief Executive of Nova Systems. Jim has more than 40 years of experience in international defense and aerospace sectors and has lived and worked in the UK, the USA, Korea, Singapore, Hong Kong and Australia. Jim joined BAE Systems in 1996 and his last executive appointment with the Group was as Chief Executive Officer of their A$5 billion annual turnover business operations in Saudi Arabia. Prior to this he was Chief Executive Officer of BAE Systems Australia for 10 years. Based in Adelaide, he drove an expansion program. Prior to his time at BAE Systems Jim worked for 18 years at aerospace Group Bombardier Shorts in legal, commercial and marketing positions. From 2018 to 2020 Jim was Chief Executive of South Australia's Department of Premier and Cabinet. He is a member of the Risk Committee and People Committee.
|
| Ms Ilona Meyer | Non-Executive Director | Mar 2022 |
Ms Meyer has over 25 years of experience as a senior executive in healthcare, agriculture and emerging technologies focusing on innovation and growth. Ilona is General Counsel and Company Secretary for Nuix Limited and prior to this role has held multiple executive roles with private and public companies, including high-growth start- ups, leading business transformation initiatives, managing multiple stakeholders, influencing industry bodies, as well as navigating high profile litigation and regulatory disputes. Prior to commencing her current role at Nuix, Ilona was General Counsel and Head of Legal & Compliance of the Boehringer Ingelheim Group for the Australian and New Zealand division. She has previously held senior legal and compliance roles at ResMed Limited, Ruralco Holdings Limited, Medtronic and 3M Australia. He is the Chair of Risk Committee.
|
| Mr Andrew Hartmann | Non-Executive Director | Dec 2022 |
Mr Hartmann is the Senior Vice President and GM Imaging Solutions at Varex Imaging Corporation and has worked overseas and in global senior roles for more than 30 years. Andrew has business expertise in the field of medical imaging devices with experience working in global roles with a focus on sales, marketing and business operations. Andrew has held senior global management roles at Phillips, Carestream and Siemens, after working in Australia that included building brands across the Asia Pacific region, the United States and Europe.
|
| Mr Richard Walter Willson | Company Secretary | May 2025 |
-
|
| Mr Kingsley Hall | Chief Executive Officer | Feb 2020 |
-
|
| Brian Gonzales | CEO Americas & Chief Scientific Officer |
-
|
|
| Kingsley Hall | Chief Executive Officer |
-
|
|
| Anthony Skeats | Chief Operating Officer |
-
|
|
| Richard Walter Willson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 109,510,922 | 16.41% |
| Varex Imaging Corporation | 54,130,053 | 8.11% |
| UBS Nominees Pty Ltd | 45,132,777 | 6.76% |
| Citicorp Nominees Pty Ltd | 26,877,856 | 4.03% |
| Billion Prima SND BHD | 26,666,667 | 4.00% |
| BNP Paribas Nominees Pty Ltd (IB AU Noms RetailClient DRP) | 19,694,285 | 2.95% |
| BNP Paribas Nominees Pty Ltd | 17,295,201 | 2.59% |
| J P Morgan Nominees Australia Pty Ltd | 15,101,375 | 2.26% |
| Mr Peter Robin Rowland | 14,194,697 | 2.13% |
| TLFTC Pty Ltd (The Lonsdale Fund A/C) | 8,385,804 | 1.26% |
| Bronte Investments Pty Ltd (McMahon Superannuation A/C) | 6,743,136 | 1.00% |
| Bindella Capital Pty Ltd | 5,659,107 | 0.85% |
| Charli Jordan Pty Ltd (Molloy Settlement A/C) | 5,115,789 | 0.77% |
| Mrs Maria David | 4,966,867 | 0.74% |
| Harman Nominees Pty Ltd (Harmanis Investment A/C) | 4,816,556 | 0.72% |
| Dr Russell Kay Hancock | 4,000,000 | 0.60% |
| Meddiscope Pty Ltd (Podesta Family A/C) | 3,244,565 | 0.49% |
| Mr Aditya Agarwal | 3,128,809 | 0.47% |
| Gowing Bros Limited | 3,068,647 | 0.46% |
| Mr David Leroy Boyles | 3,000,000 | 0.46% |